Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia not Adequately Controlled with Current Lipid-Lowering Therapy: Design and Rationale of the ODYSSEY FH Studies

BACKGROUND: Individuals with heterozygous familial hypercholesterolemia (heFH) have higher levels of low-density lipoprotein cholesterol (LDL-C) and are predisposed to premature cardiovascular disease. Alirocumab is a fully-human, monoclonal antibody targeted to proprotein convertase subtilisin/kexi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Kastelein, John J. P., Robinson, Jennifer G., Farnier, Michel, Krempf, Michel, Langslet, Gisle, Lorenzato, Christelle, Gipe, Daniel A., Baccara-Dinet, Marie T.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2014
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4074463/
https://ncbi.nlm.nih.gov/pubmed/24842558
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10557-014-6523-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados